Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Mylan Gets Final FDA Approval For Pioglitazone Tablets USP - Quick Facts

RELATED NEWS
Trade MYL now with 

Mylan Inc. (MYL: Quote) announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration or FDA for its Abbreviated New Drug Application or ANDA for Pioglitazone Tablets USP, 15 mg, 30 mg and 45 mg.

The company said that previously it had also received final approval from the FDA for its ANDA for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15 mg/500 mg and 15 mg/850 mg.

These products are the generic versions of Takeda Pharmaceutical Company's Actos Tablets and Actoplus Met Tablets, respectively, and are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has awarded Mylan 180 days of generic marketing exclusivity on both of these products.

Pioglitazone Tablets USP, 15 mg, 30 mg and 45 mg, had U.S. sales of about $2.7 billion, and Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15 mg/500 mg and 15 mg/850 mg, had U.S. sales of about $413 million for the 12 months ending June 30, 2012, according to IMS Health.

Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%. Here is a quick summary of the earnings reported after the bell on Nov. 24. 1. Amira Nature Foods Ltd (ANFI) reported net income for the second quarter of $8.3 million or $0.29 per share, compared to $5.0 million or $0.18 per share for the year-ago quarter. Excluding items, adjusted earnings...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.